ArticleBMC cancer2025
Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Berbamine Attenuates Chronic Kidney Disease-Associated Pruritus by Targeting MRGPRX1/MrgprC11 Signaling.Applied biochemistry and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBerbamine (BBM) has been reported to play an important role in the anti-inflammatory and anti-neoplastic activities. However, whether BBM mediates the anti-tumor efficacy in renal cell carcinoma (RCC) cells and the potential molecular mechanisms remain unclear.
methodsThe effects of BBM on the proliferation, colony formation, cell cycle, cell migration and invasion abilities were performed in RCC cells 786-O and OSRC2, and the effect of BBM on tumor formation was further explored. Furthermore, the effects of BBM on the expression of fat mass and obesity associated gene (FTO) and its target genes were investigated. Finally, the effects of BBM on the proliferation, and invasion of RCC cells after knockdown of FTO were detected.
resultsBBM effectively inhibited the proliferation, migration and invasion of RCC cells in a dose-dependent manner, and BBM also significantly inhibited the growth of tumor in vivo, which has fewer toxic effects on the other organs. Molecular mechanistic studies showed that BBM significantly promoted the expression of FTO mRNA and protein in RCC cells, and knock-down of FTO by siRNA transfection reversed the inhibitory effect of BBM on the growth and invasion of RCC cells.
conclusionCollectively, our findings revealed that targeting the tumor suppressive FTO by BBM is a new option to inhibit RCC cells growth and metastasis, providing a good drug candidate potential for development novel therapeutics against metastatic RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.